An App knock-in rat model for Alzheimer's disease exhibiting Aβ and tau pathologies, neuronal death and cognitive impairments
© 2021. The Author(s)..
A major obstacle in Alzheimer's disease (AD) research is the lack of predictive and translatable animal models that reflect disease progression and drug efficacy. Transgenic mice overexpressing amyloid precursor protein (App) gene manifest non-physiological and ectopic expression of APP and its fragments in the brain, which is not observed in AD patients. The App knock-in mice circumvented some of these problems, but they do not exhibit tau pathology and neuronal death. We have generated a rat model, with three familiar App mutations and humanized Aβ sequence knocked into the rat App gene. Without altering the levels of full-length APP and other APP fragments, this model exhibits pathologies and disease progression resembling those in human patients: deposit of Aβ plaques in relevant brain regions, microglia activation and gliosis, progressive synaptic degeneration and AD-relevant cognitive deficits. Interestingly, we have observed tau pathology, neuronal apoptosis and necroptosis and brain atrophy, phenotypes rarely seen in other APP models. This App knock-in rat model may serve as a useful tool for AD research, identifying new drug targets and biomarkers, and testing therapeutics.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
---|---|
Enthalten in: |
Cell research - 32(2022), 2 vom: 17. Feb., Seite 157-175 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Pang, Keliang [VerfasserIn] |
---|
Links: |
---|
Themen: |
Amyloid beta-Peptides |
---|
Anmerkungen: |
Date Completed 19.04.2022 Date Revised 08.02.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41422-021-00582-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM333275489 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM333275489 | ||
003 | DE-627 | ||
005 | 20231225221327.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41422-021-00582-x |2 doi | |
028 | 5 | 2 | |a pubmed24n1110.xml |
035 | |a (DE-627)NLM333275489 | ||
035 | |a (NLM)34789895 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Pang, Keliang |e verfasserin |4 aut | |
245 | 1 | 3 | |a An App knock-in rat model for Alzheimer's disease exhibiting Aβ and tau pathologies, neuronal death and cognitive impairments |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.04.2022 | ||
500 | |a Date Revised 08.02.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021. The Author(s). | ||
520 | |a A major obstacle in Alzheimer's disease (AD) research is the lack of predictive and translatable animal models that reflect disease progression and drug efficacy. Transgenic mice overexpressing amyloid precursor protein (App) gene manifest non-physiological and ectopic expression of APP and its fragments in the brain, which is not observed in AD patients. The App knock-in mice circumvented some of these problems, but they do not exhibit tau pathology and neuronal death. We have generated a rat model, with three familiar App mutations and humanized Aβ sequence knocked into the rat App gene. Without altering the levels of full-length APP and other APP fragments, this model exhibits pathologies and disease progression resembling those in human patients: deposit of Aβ plaques in relevant brain regions, microglia activation and gliosis, progressive synaptic degeneration and AD-relevant cognitive deficits. Interestingly, we have observed tau pathology, neuronal apoptosis and necroptosis and brain atrophy, phenotypes rarely seen in other APP models. This App knock-in rat model may serve as a useful tool for AD research, identifying new drug targets and biomarkers, and testing therapeutics | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
650 | 7 | |a Amyloid beta-Protein Precursor |2 NLM | |
700 | 1 | |a Jiang, Richeng |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Wei |e verfasserin |4 aut | |
700 | 1 | |a Yang, Zhengyi |e verfasserin |4 aut | |
700 | 1 | |a Li, Lin-Lin |e verfasserin |4 aut | |
700 | 1 | |a Shimozawa, Makoto |e verfasserin |4 aut | |
700 | 1 | |a Tambaro, Simone |e verfasserin |4 aut | |
700 | 1 | |a Mayer, Johanna |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Baogui |e verfasserin |4 aut | |
700 | 1 | |a Li, Man |e verfasserin |4 aut | |
700 | 1 | |a Wang, Jiesi |e verfasserin |4 aut | |
700 | 1 | |a Liu, Hang |e verfasserin |4 aut | |
700 | 1 | |a Yang, Ailing |e verfasserin |4 aut | |
700 | 1 | |a Chen, Xi |e verfasserin |4 aut | |
700 | 1 | |a Liu, Jiazheng |e verfasserin |4 aut | |
700 | 1 | |a Winblad, Bengt |e verfasserin |4 aut | |
700 | 1 | |a Han, Hua |e verfasserin |4 aut | |
700 | 1 | |a Jiang, Tianzi |e verfasserin |4 aut | |
700 | 1 | |a Wang, Weiwen |e verfasserin |4 aut | |
700 | 1 | |a Nilsson, Per |e verfasserin |4 aut | |
700 | 1 | |a Guo, Wei |e verfasserin |4 aut | |
700 | 1 | |a Lu, Bai |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cell research |d 1997 |g 32(2022), 2 vom: 17. Feb., Seite 157-175 |w (DE-627)NLM09215381X |x 1748-7838 |7 nnns |
773 | 1 | 8 | |g volume:32 |g year:2022 |g number:2 |g day:17 |g month:02 |g pages:157-175 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41422-021-00582-x |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 32 |j 2022 |e 2 |b 17 |c 02 |h 157-175 |